CONMED Corp (CNMD) Form 10-Q — Oct 28, 2026
CONMED's Q3 2026 net income jumped to $19.8 million ($0.66 EPS) from just $2.9 million ($0.09 EPS) a year ago, driven by a 720 basis point gross margin expansion to 56.4% and lower cost of sales. Net sales slipped 0.7% to $335.6 million, but the decline was almost entirely the planned exit from gastroenterology products; orthopedic surgery sales grew 7.7% on strength in sports medicine, visualization, and BioBrace, while remaining general surgery lines like AirSeal kept growing.
Key figures
- Eps
- 0.66
- Revenue
- 335557000
- Net Income
- 19796000
- Total Debt
- 815866000
- Total Assets
- 2304462000
- Cash Position
- 47972000
- Shares Outstanding
- 29803323
- Q3 2025 eps
- 0.09
- Nine month revenue
- 996090000
- Q3 2025 net income
- 2859000
- Term a2 loan drawn
- $450.0 million
- Variable rate debt
- $664.4 million
- Gross margin q3 2025
- 49.2%
- Gross margin q3 2026
- 56.4%
- Ieepa tariff refunds
- $10.2 million
- Q3 buyback avg price
- 45.71
- Revolver outstanding
- $180.0 million
- Nine month net income
- 56695000
- Q3 shares repurchased
- 137043
- Nine month eps diluted
- 1.87
- Gain on debt extinguishment
- $8.1 million
- Buyback remaining authorization
- 100083085
- Convertible notes repurchase cost
- $637.2 million
- Convertible notes repurchased principal
- $645.2 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.